Eagle Health Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Eagle Health Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-82,144	Closed	-$21.4M	–	31
2022 Q1	$21.4M	Hold	82,144	–	–	5.28%	7
2021 Q4	$18M	Buy	82,144 +52,600	+178%	+$10.2M	4.4%	10
2021 Q3	$5.36M	Sell	29,544 -40,600	-58%	-$7.93M	1.7%	21
2021 Q2	$14.1M	Sell	70,144 -18,300	-21%	-$3.83M	4.85%	10
2021 Q1	$19M	Buy	88,444 +36,444	+70%	+$8M	7.46%	2
2020 Q4	$12.3M	Buy	+52,000	New	+$11.9M	7.86%	3

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eagle Health Investments's VRTX Position: Q2 2022 in Review

Eagle Health Investments sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 82,144 shares — an estimated $21.4M sold.

Eagle Health Investments first reported a position in VRTX in Q4 2020 and held it in 6 quarters. The position peaked at $21.4M in Q1 2022. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Eagle Health Investments reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Eagle Health Investments sold 82,144 Vertex Pharmaceuticals shares in Q2 2022, an estimated $21.4M.
Eagle Health Investments first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Eagle Health Investments's Vertex Pharmaceuticals position peaked at $21.4M in Q1 2022.
1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Eagle Health Investments's 13F filing for Q2 2022, filed 11 Aug 2022.